曲妥珠单抗联合新辅助化疗对HER-2阳性乳腺癌患者近远期疗效的影响  被引量:18

Efficacy of Trastuzumab Joint Neoadjuvant Chemotherapy for HER-2 Positive Breast Cancer

在线阅读下载全文

作  者:孙愚[1] 李帅[1] 罗婷[1] 郑鸿[1] 鄢希[1] 

机构地区:[1]四川大学华西医院,618300

出  处:《实用癌症杂志》2016年第8期1355-1356,共2页The Practical Journal of Cancer

摘  要:目的探讨曲妥珠单抗联合新辅助化疗对表皮生长因子受体-2(HER-2)阳性乳腺癌患者的疗效。方法选取HER-2阳性乳腺癌患者58例,随机分为观察组和对照组,各29例。对照组给予表柔比星联合多西他赛的方案进行新辅助化疗,观察组在对照组的基础上给予曲妥珠单抗治疗。比较两组患者的近期、远期疗效。结果观察组有效率(RR)及病理完全缓解(p CR)率明显优于对照组,5年总生存率(OS)及5年无病生存率(DFS)明显高于对照组。结论曲妥珠单抗联合新辅助化疗治疗HER-2阳性乳腺癌近期疗效显著,并可有效改善患者预后,值得临床推广应用。Objective To investigate the efficacy of trastuzumab joint neoadjuvant chemotherapy for hers-2 positive breast cancer. Methods 58 hers-2 positive breast cancer patients were randomly divided into the observation group and the con- trol group, each with 29 cases. The control group was given epirubicin combined with docetaxel neoadjuvant chemotherapy, the ob- servation group on the basis of the control group was given trastuzumab. Short-term and long-term efficacy of the 2 groups were compared. Results Efficient (RR) and pathological complete response (pCR) rate of the observation group were significantly better than those of the control group ,the 5-year overall survival (OS) and 5-years disease-free survival (DFS) were significantly higher than those of the control group. Conclusion Trastuzumab joint neoadjuvant chemotherapy for hers-2 positive breast cancer has significant short-term efficacy, and can effectively improve the prognosis of patients, it is worthy of clinical popularization and application.

关 键 词:曲妥珠单抗 新辅助化疗 HER-2 乳腺癌 

分 类 号:R737.9[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象